Neko Health, the preventive health-scanning company co-founded by Spotify co-founder Daniel Ek and Hjalmar Nilsonne, has closed a $700 million Series C funding round1,2. The round was led by Lightspeed Venture Partners and co-led by O.G. Venture Partners, with participation from existing investors Atomico, General Catalyst, and Lakestar, alongside new backers Liberty City Ventures, Positive Sum, and BDT & MSD. David Ofer of O.G. Venture Partners will join Neko Health's Board of Directors, subject to regulatory approval.
The raise follows a $260 million Series B completed in January 2025. The Financial Times characterized the new capital as funding a "US push".
Neko Health's core product is the Neko Health Scan, a 60-minute, non-invasive, radiation-free health assessment that captures millions of health data points using proprietary sensors and blood analysis. The scan assesses skin health — including moles and marks — biomarkers for pre-diabetes risk, blood abnormalities, and risk factors linked to metabolic syndrome, stroke, and heart attack. Results are delivered on-site within minutes and discussed during an in-person consultation with a medical professional. The scan is priced at £299 in the UK and 2,750 SEK in Sweden.
The company launched in February 2023 and has since expanded its footprint across Sweden and the UK, including clinics in Manchester, Birmingham, and multiple London locations. Neko opened its latest clinic in Stockholm last month. Over 350,000 people have registered for a Neko Health Scan, and more than 100,000 members have completed one. On average, 75 percent of members book and prepay for a scan for the following year at the end of their appointment.
Neko reported that five of seven key biomarkers showed statistically significant improvement between a member's first and second scans. The company also found that three in four returning members with previously identified severe or life-threatening conditions were in good health or had their conditions under control.
Three weeks before the funding announcement, Neko rolled out what it described as its most significant scan advancement to date: the addition of body composition measures and clinician review of wearable data, now live across all clinics. The company's next-generation medical devices — Derma-2, ECHO-2, and Spectrum-2 — are set to be rolled out across all Neko clinics in the coming months.
ANALYSIS The AI relevance here centers on Neko Health's sensor-driven, data-intensive scanning model, which relies on capturing and processing millions of health data points per session to generate rapid, personalized results. ANALYSIS With more than 100,000 completed scans and continued investment in next-generation hardware, the platform's approach is consistent with increasing dependence on machine learning for pattern recognition across skin, blood, and metabolic biomarkers. ANALYSIS The $700 million raise — nearly triple the $260 million Series B — provides substantial capital for the reported US expansion effort.